DexCom Inc. Files 2025 Proxy Statement
Ticker: DXCM · Form: DEF 14A · Filed: Mar 27, 2025 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | DEF 14A |
| Filed Date | Mar 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: DXCM
TL;DR
DexCom's proxy statement is out, detailing exec pay and governance for 2024. Vote wisely.
AI Summary
DexCom Inc. filed its DEF 14A on March 27, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key figures related to stock awards for both PEO and Non-PEO members are presented for the fiscal years 2020 through 2024.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions on company matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing detailing executive compensation and corporate governance, not indicating new operational risks.
Key Numbers
- 2024 — Fiscal Year End (Data presented for this year)
- 2023 — Fiscal Year End (Data presented for this year)
- 2022 — Fiscal Year End (Data presented for this year)
- 2021 — Fiscal Year End (Data presented for this year)
- 2020 — Fiscal Year End (Data presented for this year)
Key Players & Entities
- DEXCOM INC (company) — Filer
- 0001093557-25-000100.txt (document) — Filing document name
- 20250327 (date) — Filing date
- 20250508 (date) — Period of report
- 3841 (number) — Standard Industrial Classification
- DE (state) — State of incorporation
- 1231 (date) — Fiscal year end
- 000-51222 (number) — SEC file number
- SAN DIEGO (city) — Business address city
- 92121 (zip_code) — Business address zip
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit proxies from shareholders when a company is holding an annual or special meeting of security holders. It provides detailed information about matters to be voted on, including director elections, executive compensation, and other corporate actions.
When was this DEF 14A filing submitted by DexCom Inc.?
DexCom Inc. submitted this DEF 14A filing on March 27, 2025.
What fiscal period does this filing primarily cover?
This filing pertains to the fiscal year ending December 31, 2024, and includes comparative data for previous fiscal years (2020-2023).
What specific types of compensation data are detailed in the filing for PEO and Non-PEO members?
The filing details deductions for amounts reported under stock awards, year-end fair value of equity awards granted that remained unvested, and vesting date fair value for awards granted and vested in the same fiscal year for both PEO (Principal Executive Officer) and Non-PEO (Non-Principal Executive Officer) members.
Where is DexCom Inc. headquartered?
DexCom Inc. is headquartered in San Diego, California, with its business address listed as 6340 Sequence Drive, San Diego, CA 92121.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 27, 2025 regarding DEXCOM INC (DXCM).